Recent Analysts’ Ratings Changes for Poseida Therapeutics (PSTX)

Poseida Therapeutics (NASDAQ: PSTX) has recently received a number of price target changes and ratings updates:

• 12/2/2024 – Poseida Therapeutics was downgraded by analysts at Piper Sandler from an “overweight” rating to a “neutral” rating. They now have a $10.00 price target on the stock.
• 11/26/2024 – Poseida Therapeutics had its “neutral” rating reaffirmed by analysts at BTIG Research.
• 11/26/2024 – Poseida Therapeutics had its “neutral” rating reaffirmed by analysts at HC Wainwright. They now have a $9.00 price target on the stock, down previously from $20.00.
• 11/26/2024 – Poseida Therapeutics had its “market perform” rating reaffirmed by analysts at William Blair.
• 11/26/2024 – Poseida Therapeutics was downgraded by analysts at Cantor Fitzgerald from a “strong-buy” rating to a “hold” rating.
• 11/15/2024 – Poseida Therapeutics had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $20.00 price target on the stock.
• 11/8/2024 – Poseida Therapeutics had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $20.00 price target on the stock.
• 10/30/2024 – Poseida Therapeutics had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $20.00 price target on the stock.
• 10/17/2024 – Poseida Therapeutics had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $20.00 price target on the stock.

Poseida Therapeutics Trading Down 0.9 %

NASDAQ:PSTX opened at $9.33 on Friday. Poseida Therapeutics, Inc. has a one year low of $1.87 and a one year high of $9.44. The company has a market cap of $909.30 million, a PE ratio of -14.81 and a beta of 1.64. The company has a debt-to-equity ratio of 0.68, a current ratio of 3.20 and a quick ratio of 3.20. The firm has a 50-day moving average of $3.76 and a 200-day moving average of $3.27.

Insiders Place Their Bets

In other news, Chairman Mark J. Gergen sold 30,000 shares of the stock in a transaction dated Tuesday, November 26th. The shares were sold at an average price of $9.27, for a total value of $278,100.00. Following the completion of the sale, the chairman now owns 651,291 shares in the company, valued at $6,037,467.57. This represents a 4.40 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Corporate insiders own 2.90% of the company’s stock.

Institutional Investors Weigh In On Poseida Therapeutics

A number of institutional investors have recently added to or reduced their stakes in the company. Virtu Financial LLC bought a new position in shares of Poseida Therapeutics in the third quarter valued at approximately $37,000. Barclays PLC boosted its position in Poseida Therapeutics by 132.7% in the third quarter. Barclays PLC now owns 120,464 shares of the company’s stock worth $345,000 after purchasing an additional 68,688 shares during the last quarter. XTX Topco Ltd grew its stake in Poseida Therapeutics by 47.1% in the 3rd quarter. XTX Topco Ltd now owns 182,888 shares of the company’s stock valued at $523,000 after purchasing an additional 58,587 shares during the period. State Street Corp increased its position in shares of Poseida Therapeutics by 2.3% during the 3rd quarter. State Street Corp now owns 1,710,565 shares of the company’s stock valued at $4,892,000 after purchasing an additional 38,770 shares during the last quarter. Finally, Fred Alger Management LLC bought a new stake in shares of Poseida Therapeutics during the 3rd quarter worth $369,000. 46.87% of the stock is owned by institutional investors.

Poseida Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company's development candidates for Heme Malignancies includes P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; P-CD19CD20-ALLO1, which is in Phase I trial for treating B cell malignancies and other autoimmune diseases; P-BCMACD19-ALLO1, an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for treating multiple myeloma; and P-CD70-ALLO1 under preclinical development to treat hematological indications.